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ABSTRACT  
Outcome of HIV positive patients presenting with renal failure at  
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) 
Background 
The majority of the 33.4 million people infected with HIV worldwide reside in sub-Saharan Africa. 
The HIV prevalence amongst young South Africans (ages 15- 49) is 16%. HIV is the third leading 
cause of ESRD in African - Americans aged 20-64 in the United States. There is a paucity of data 
regarding the prevalence of acute kidney injury (AKI) in HIV patients in sub-Saharan Africa. 
Methods 
A retrospective review of 101 HIV positive patients presenting with renal failure at the CMJAH from 
1st October 2005 until 31st October 2006 was undertaken. There were 50 HIV positive patients with 
presumed AKI that were compared to 90 HIV negative patients with AKI.   
Results 
A total of 684 patients presented with renal failure, 101(14.8%) of whom were HIV positive. Ninety-
nine of the HIV positive patients were black and 56 were male. The mean age of HIV positive 
patients with renal failure was 38 years. Fifty-seven patients presented with AKI (seven patients 
were excluded due to lack of records), 21 with acute on chronic renal failure and 23 with chronic 
renal failure. The causes of AKI in the HIV positive group included sepsis (62%), haemodynamic 
instability (20%), toxins (10%), urological obstruction (8%) and miscellaneous (10%).  
The common underlying aetiologies of the 90 HIV negative patients studied presenting with AKI 
were sepsis (43%), haemodynamic instability (17%), toxins (7%), urological obstruction (8%) and 
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miscellaneous (23%). Forty-seven (52%) of these HIV negative patients recovered. Forty-two (47%) 
patients died, compared with 22 (44%) patients in the HIV positive group.  
Hyponatraemia, hyperkalaemia, hypochloraemia and acidosis were more common in the HIV 
positive patients. Dialysis was initiated in 36% of HIV positive patients with AKI. There were more 
HIV positive patients that recovered with supportive care, including fluid therapy when compared to 
HIV negative patients. Recovery was noted to be more rapid in the HIV positive group. Using 
survival and death as the outcome there was no difference between the HIV positive and the HIV 
negative group presenting with AKI (p<0.7173). 
Discussion 
HIV positive patients presented with renal failure at a younger age – a mean age of 38 years in this 
study. Previous studies have shown mean ages ranging from 35 years to 46.7 years. The majority of 
the HIV positive patients presenting with renal failure were black (98%). The racial predominance is 
different to that of other countries which might be due to epidemiological factors. The gender 
differences were similar when compared to other studies. Sepsis was the more common aetiological 
factor of AKI (62% of HIV positive patients compared to 43% of HIV negative patients). HIV 
positive patients with AKI presented at an advanced stage of immunosuppression (more than 50% 
had CD4<100cells/µl). Electrolyte disturbances were common in HIV positive patients with AKI. 
Conclusion 
HIV positive patients with AKI presented with advanced immunosuppression. Sepsis was the most 
common aetiology of AKI. Supportive management or renal replacement therapy resulted in 
recovery in a large number of patients.HIV positive patients should be treated acutely just as HIV 
negative patients and should not be excluded on the basis of their HIV status. Dialysis should be 
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offered when indicated and aggressive fluid resuscitation should be emphasized. Outcomes were 
similar in HIV positive and HIV negative patients presenting with AKI. 
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PREFACE 
Kidney disease is common in HIV positive patients, occurring in 30% of patients, and is a common 
cause of end-stage renal disease (ESRD) (Gupta et al. 2005). Data on HIV patients with AKI in 
developing countries is scanty. 
This research report is a retrospective review of all patients presenting to the adult renal unit at 
Charlotte Maxeke Johannesburg Academic Hospital between 1st October 2005 and 31st October 
2006. The spectrum of renal disease in HIV positive patients is reviewed. The presentation of renal 
disease in HIV positive patients, demographic, clinical and laboratory data, dialysis and mortality 
were evaluated.
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INTRODUCTION 
1.1 Background and History 
The Human Immunodeficiency Virus (HIV) was first identified in 1981 (Gottlieb et al. 1981) and 
was subsequently reported to affect the kidney (Rao et al. 1984). HIV is a lentivirus (a member of 
the retrovirus family) that causes the Acquired Immunodeficiency Syndrome (AIDS), which leads 
to life-threatening opportunistic infections. HIV infects and destroys CD4 T cells, ultimately leading 
to the loss of immune control of multiple pathogens and cancers (Douek et al. 2009). HIV 
associated nephropathy is a common cause of end-stage renal disease (ESRD) (Gupta et al. 2005).  
 
                       
       Figure 1   Human Immunodeficiency Virus structure  (NIAID 2010) 
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1.2 Prevalence of HIV infection in sub-Saharan Africa 
 
In 2006, sub-Saharan Africa accounted for 72% of all known deaths due to AIDS worldwide. 
During this period, the population of sub-Saharan Africa was 800 million people (12% of the 
world’s population). Of the 33.4 million people worldwide living with HIV, 22.4 million reside in 
sub-Saharan Africa. The burden of disease is evident in that sub-Saharan Africa, while having over 
10% of the world’s population, accounts for more than two-thirds of those infected with HIV 
(UNAIDS 2009).   
The prevalence of HIV infection exceeds 10% in nine countries in Southern Africa. About 1.9 
million adults and children became infected with HIV in 2008 and a further 1.4 million deaths were 
attributable to AIDS. The average life expectancy is below 40 years. Women in South Africa 
account for 60% of all HIV infections (UNAIDS 2009).  
The number of people newly infected with HIV fell from 2.2 million people in 2001, to 1.8 million 
people in 2009 (see Table 1).With an estimated 5.6 million (5.4 million – 5.8 million) HIV positive 
people, South Africa continues to have the world’s largest HIV epidemic (UNAIDS 2010). 
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Table 1   Sub-Saharan HIV statistics (UNAIDS 2010) 
 
 
 
 
 
Figure 2   HIV trends in sub-Saharan Africa (UNAIDS 2010) 
 
 
4 
 
 
 
 
 
 
 
 
  Figure 3   HIV worldwide (UNAIDS 2009) 
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1.3 Presentation of kidney disease in HIV positive patients 
Kidney disease can present as acute kidney injury (AKI), acute on chronic renal failure (AOCRF) 
and chronic kidney disease (CKD) (Table 2).  In the developed nations the spectrum of pathology 
has changedwith the advent of HAART. Since the advent of HAART, morbidity and mortality from 
HIV infection has decreased substantially (Palella et al. 1998; Hogg et al. 2001); however HIV 
positive patients on HAART are susceptible to complications of nephrotoxicity. In sub-Saharan 
Africa, the majority of patients who are admitted with HIV infection are treatment-naive and 
present with AKI secondary to pre-renal failure and opportunistic infections.  
 
§ Electrolyte and acid-base disturbances 
§ Acute Kidney Injury (AKI) 
§ Chronic Kidney Disease (CKD)  
o HIV-associated glomerulonephropathies  
o Intrinsic renal disease unrelated to HIV itself 
(e.g. diabetes mellitus and hypertension) 
§ Acute on Chronic Kidney Disease  
§ Side effects related to treatment of HIV, which include ART and drugs used to treat 
complications of HIV 
§ Long term metabolic side-effects of ART 
 
  Table 2   Spectrum of renal disease in HIV infection 
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1.4 HIV and Acute Kidney Injury  
Acute kidney injury (previously termed acute renal failure) occurs in 5-7% of hospital admissions 
and affects 30% of HIV positive  patients admitted to ICU (Kathleen 2008). Acute kidney injury 
occurs over hours to days and is characterized by an abrupt decline in GFR, rising blood urea and 
serum creatinine, the loss of water and salt homeostasis and life-threatening metabolic 
consequences.  
1.4.1 Definition 
There are many definitions of AKI (more than 30) and the lack of a concise universal definition has 
made it difficult to compare data and to guide therapy. The Infectious Diseases Society of America 
defined AKI in HIV- seropositive patients as a serum creatinine level greater than 1.5mg/dL 
(132.6µmol/L) or a 1.3-fold increase above the laboratory baseline that recovers within 3 months. 
An international initiative has attempted to come to a consensus regarding the definition of AKI 
and hence the RIFLE classification (Table 3) was developed (Bellomo et al. 2004). There are three 
severity categories (risk, injury, loss) and two clinical outcome categories (loss and end stage renal 
disease). A recent study from London classified patients with AKI using a GFR reduction of 40% 
from the admission creatinine (Ibrahim et al. 2010). 
 
  Table 3   RIFLE criteria (Bellomo et al. 2004) 
 
Class  GFR Criteria  Urine Output criteria  
Risk  Serum creatinine X 1.5  <0.5ml/kg/h X 6h  
Injury  Serum creatinine X 2 <0.5ml/kg/hr X 12h  
Failure  Serum creatinine X 3 
or serum creatinine >355umol/L with an acute rise > 44umol/L  
<0.3ml/kg/h X 24h or anuria X 
12h  
Loss  Persistent acute renal failure > 4 weeks   
ESRD  End stage renal disease > 3 months   
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1.4.2 Classification 
Acute kidney injury is divided into pre-renal, intra-renal (intrinsic) and post-renal failure (Table 4). 
Pre-renal failure is the most common presentation and can progress to acute tubular necrosis 
(ATN), which once developed may be irreversible (Kathleen 2008). Post-renal presentations are 
frequently reversible, hence the cause of obstruction needs to be appropriately investigated.  
Pre-renal Intra-renal Post-renal 
Hypovolaemia   
dehydration 
   diarrhoea 
   vomiting    
   haemorrhage 
Sepsis 
Heart failure 
Pancreatitis 
Renal vasoconstriction 
NSAIDS  
 
ATN 
sepsis 
   ischaemia 
   hypotension 
   toxins 
   rhabdomyolysis 
Drugs: 
NSAIDS , amphotericin B, tenofovir, 
    contrast, chemotherapy 
Infection: 
bacteria: mycobaceria tuberculosis,  
    mycobacteria other than TB (MOTT)   
   viruses: herpes, cytomegalovirus,    
    varicella zoster virus, BK virus 
   fungi : aspergillus, cryptococcus,   
     histoplasmosis, candida,  mucormycosis 
   parasites : pneumocystis, toxoplasmosis,  
    microsporia  
Glomerulopathies 
  HIVAN 
  HIVICK 
other : IgA, acute post-infectious, 
     lupus nephritis 
   RPGN secondary to rifampicin  
   HUS/TTP 
Acute Interstitial Nephritis 
Drugs: NSAIDS, indinavir, bactrim,  
Tumours 
renal cell carcinoma, lymphoma 
   multiple myeloma, Kaposi's sarcoma 
Obstruction 
crystalluria  
    high dose bactrim  
    acyclovir 
  nephrolithiasis 
    indinavir 
    atazanavir 
  hyperuricosuria  
    chemotherapy 
 Herpes related    
   neurogenic bladder 
 Prostatic hypertrophy   
   malignancy (men) 
 
 
 
Table 4   Classification of AKI in HIV infection (Fabian and Naicker. 2009) 
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The most common form of renal replacement therapy for HIV positive patients is haemodialysis 
(Ahuja et al. 2003). For chronic dialysis, the outcomes between haemodialysis and peritoneal 
dialysis are equivalent (Abbott et al. 2003). Disadvantages of haemodialysis include the risk of 
needle stick injuries to healthcare providers. Disadvantages of peritoneal dialysis include increased 
protein losses and a potential for severe peritonitis. For acute dialysis in HIV positive patients, the 
usual indications apply as for HIV negative individuals (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
      Table 5   Proposed criteria for initiation of RRT in patients with AKI  (Lameire et al. 2005) 
 
Acute kidney injury in hospitalized ART-naive HIV positive patients is associated with a six-fold 
higher risk of in-hospital mortality (Wyatt et al. 2006). In the HIV negative population AKI occurs 
in about 19% of patients with moderate sepsis, 23% of those with severe sepsis and 51% of those 
with septic shock when blood cultures are positive (Schrier et al. 2004).  
Acute kidney injury incidence rates vary between 0.9% to 20% and mortality rates from 25% to 
80% in the HIV negative population (Lameire et al. 2005). The epidemiology of AKI in Africa was 
reviewed in 2008 (Table 6). Prior to this article there were very few publications about the 
oliguria : urine output < 200ml in 12hours 
anuria : urine output  < 50ml in 12hours 
hyperkalaemia : K > 6,5mmol/L 
severe acidosis : pH < 7 
azotaemia : urea concentration >30mmol/L 
uraemic encephalopathy 
uraemic neuropathy/myopathy 
uraemic pericarditis 
plasma sodium : Na >155mmol/L or <120mmol/L 
Hyperthermia 
drug overdose with dialyzable toxin 
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incidence of AKI in Africa. A review of causes per region was undertaken and the majority of 
causes of AKI included infections (HIV and malaria), diarrhoea and nephrotoxins. AKI in Africa is 
challenging due to the late presentation and a lack of resources (Naicker et al. 2008). 
 
 
 
 
Table 6  Causes of AKI in Africa (Naicker et al. 2008) 
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1.4.3 International Literature (HIV and AKI) 
Six retrospective studies focusing on HIV and AKI were reviewed (see Appendix 5). Four of these 
studies reviewed HIV positive hospitalized patients and two studies reviewed ambulatory HIV 
positive patients with AKI. 
 In a group of 754 ambulatory HIV positive patients (from the USA) observed between 2000 and 
2002, 111 AKI events occurred in 71 subjects; mean age was 40 years and 61% were black. AKI 
was more common in men (68%), in those with CD4<200cells/mm³ and HIV RNA levels >10 000 
copies/ml. Diarrhoea, nausea and vomiting, liver failure and infections were the most common 
causes of pre-renal failure occurring in 38% of patients. AKI not recovering after 24 hours of 
hydration was defined as acute tubular necrosis (ATN). Those with low CD4 counts were more 
likely to develop ATN. Ischaemic or noncontrast drug nephrotoxicity accounted for the majority of 
intrinsic renal failure (Franceschini et al. 2005). 
There were two cases of thrombotic thrombocytopaenic purpura – haemolytic uraemic syndrome 
(TTP-HUS). Over 50% of all renal events were associated with infections. Drugs associated with 
AKI included antibiotics (amphotericin B, aminoglycosides, vancomycin) and antiretroviral agents 
(indinavir, tenofovir and nevirapine). AKI was often seen in patients with AIDS, Hepatitis C and 
those on HAART.  About one-quarter of the patients had hepatitis C virus co-infection. The median 
CD4 cell count was over 350cells/µl and about one-third had a CD4 count <200cells/µl. Repeat 
episodes of AKI were more frequent in those with advanced HIV disease. Renal replacement 
therapy was required in 5 patients (Franceschini et al. 2005). 
In France, a review over 8.5 years identified 92 hospitalized HIV positive patients with AKI. The 
mean age was 35 years and 88% were black. Eighty-two % of patients had overt AIDS and the 
mean CD4 count at baseline was 76 cells/µl. The mean serum creatinine on admission was 
480µmol/L. The common causes of AKI were sepsis (75%), HUS (32%) and ATN (26%).  The 
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mortality rate was 20%. Renal biopsies were performed in 60 patients; HIVAN was present in 23% 
(Peraldi et al. 1999). This study claimed an academic interest in thrombotic microangiopathy but 
nevertheless highlights the importance of renal biopsies.  
One of the largest registries examined the incidence and predictors of AKI before and after the 
introduction of HAART in the USA.  There were 52 580 HIV infected patients reviewed in 1995 
and 25 114 in 2003. In the post-HAART cohort (2003), 1516 (6%) presented with AKI. The mean 
age was 46.7 years and 54.6% were black. Males accounted for 46.7 % of the patients reviewed. 
The in-hospital mortality was 26.6%. Acute kidney injury was reported more often during 
hospitalizations for HIV-infected patients than for uninfected patients in 1995 (2.9% vs 1.0%) and 
in 2005 (6.0% vs 2.7%) (Wyatt et al. 2006). The problem with observational databases is that the 
diagnosis of AKI is based on clinical judgment and no laboratory data was reviewed.  
The ‘RIFLE’ criteria was used in a retrospective review of critically ill HIV positive patients from 
Portugal between 2002 and 2006. Acute kidney injury occurred in 46 patients. Of these, 12 patients 
(26%) were classified in class ‘R’, 9 patients (19,5%) were in class ‘I’, and 25 patients (43%) were 
in class ‘F’. The mean age was 42.7 years and 60% were black. Males accounted for 40% of cases. 
Sepsis was present in 84% of patients. Two patients presented with thrombotic thrombocytopaenic 
purpura (TTP). Renal replacement therapy was prescribed for 7 patients. The overall mortality was 
43.3% (Lopes et al. 2007).   
The outcome of severe acute renal failure in patients with AIDS was reviewed retrospectively over 
almost a decade at the Renal Division at Kings County Hospital Centre in New York where 146 
HIV positive patients (pre-HAART) with a serum creatinine concentration of 530µmol/L or higher 
were included in the study. This group was compared with a group of 306 HIV negative patients 
(Table 7). Ninety-one % of the HIV positive patients with AKI were less than 50 years of age 
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compared with only 33% of the HIV negative patients. Septicaemia was responsible for AKI in 
75% of patients in the HIV positive group compared to 39% in the HIV negative group.  
Thirty-six % of the HIV positive patients were terminally ill and could not be treated by aggressive 
dialysis, compared with only 18% in the elderly HIV negative group. Recovery of renal function 
and mortality were determined by the patient’s haemodynamic situation and not by HIV status. The 
impact of AIDS on AKI was illustrated by the fact that despite being younger, over one third of the 
patients confined to the intensive care units with multi-organ dysfunction and overwhelming sepsis 
were considered to be agonal and untreatable.  It was also noted that the number of patients seen 
over the decade increased substantially (Rao et al. 1995). 
 HIV positive (%) HIV negative (%) 
No. of patients 146 306 
Sex (male/female) 113 / 33 197 / 109 
Age  mean (years) 38.4 55.2 
Aetiology of AKI:   Sepsis 76/146 (52) 73/306 (24) 
                                 Nephrotoxins 33/146 (23) 45/306 (15) 
                                 Miscellaneous 37/146 (25) 53/306 (17) 
                                 Urinary obstruction 0/146 (0) 54/306 (17) 
No. of agonal patients not dialyzed 53 (36) 57 (18) 
Supportive care (no dialysis) 20 (14) 42 (14) 
Renal recovery in dialyzed patients 41/73 (56) 98/207 (47) 
Overall renal recovery 58/93 (62) 133/249 (53) 
Overall mortality 88/146 (60) 173/306 (56) 
 
Table 7   Comparison of AKI in HIV positive and HIV negative patients   (Rao et al. 1995) 
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A recent review from London, has shown that immunodeficiency and renal impairment were risk 
factors for HIV-associated acute kidney injury. This review of almost a decade (January 1999 to 
December 2008) found that the incidence of AKI was 2.8 episodes per 100 000 person-years. This 
study included patients with GFR less than 60ml/min and also included patients if their GFR was 
reduced by more than 40% from baseline and the duration of the AKI was less than 90 days. There 
were 2556 patients reviewed and 184 patients (7.2%) experienced AKI. Forty-five percent of the 
patients were receiving anti-retrovirals. Opportunistic infections were the commonest causes of 
AKI in patients who had CD4<50 cells/µl. Death was more common in those patients with AKI 
compared to those without AKI (32.1 vs 3.7%, p<0.001).There was an increase in the incidence of 
AKI at lower CD4 counts and lower glomerular filtration rates. Ethnicity, hepatitis B or C 
coinfection, exposure to combination antiretroviral therapy with or without indinavir, tenofovir or 
atazanavir and HIV viraemia were not associated with AKI (Ibrahim et al. 2010). 
A retrospective review of 117 HIV patients between 2002 and 2007 (17% on HAART) requiring 
acute dialysis in Cape Town showed that higher CD4 counts (OR=0.994), lower pre-dialysis serum 
creatinine (<1230µmol/l) and longer hospitalization(OR=0.93) significantly increased survival. The 
median age was 34 years (range 29.0-49.0) with a male predominance (53.8%). The median CD4 
count was 164 cells/mm³ and 32.5% of subjects had a CD4 > 200cells/mm³. A lower mean CD4 
count (132 cells/mm³) was found for patients who died. The median pre-dialysis creatinine was 
988µmol/l (range 729.8-1230.0). HBsAg was positive in four patients. The median period of 
hospitalization was 15.0 days. Sepsis was present in 50.4% of patients.Forty-eight patients (41%) 
died. There was a good chance of survival when the diagnosis was ATN and when the CD4 count 
was more than 200cells/mm³(Arendse et al. 2011). 
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1.5 HIV and Chronic Kidney Disease  
Chronic Kidney Disease (CKD) is defined by : 
1) Evidence of structural or functional kidney damage (abnormal urinalysis, imaging studies or 
histology) present for at least 3 months with or without a decrease in GFR ; or  
2) Decreased kidney function (GFR<60ml/min per 1.73m²). 
 
CKD is classified into 5 stages (Table 8) according to the GFR, which is calculated either using the 
Cockcroft-Gault equation or the MDRD (Modification of Diet in Renal Disease) equation (Table 9). 
Stage Description GFR (ml/min per 1,73m²) 
I Kidney damage with normal or increased GFR ≥90 
II Kidney damage with mildly decreased GFR 60-89 
III Moderately decreased GFR 30-59 
IV Severely decreased GFR 15-29 
V Kidney failure <15 (or dialysis) 
 
 Table 8   Stages of CKD(Levey et al. 2002) 
 
 
Cockcroft-Gault 
equation 
 
(140 -  age ) X  body weight (kg)X  (0.85 females) 
                                    0.82 X  serum creatinine 
 
 
MDRD equation 
 
186 * [s-Creat (µmol/l)* 0.011312] –1.154 * [age] -0.203 
* [0.742 if patient is female] * [1.212 if patient is black] 
 
 Table 9   GFR calculation (Levey et al. 2002) 
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1.5.1  HIV-associated nephropathy 
HIV-associated nephropathy (HIVAN) is an entity that is now thought to be caused by a direct 
effect on renal cells by the Human Immunodeficiency Virus. HIVAN is the third leading cause of 
ESRD in African-Americans aged 20-64 in the United States (Ross et al. 2000), preceded only by 
diabetes and hypertension. Over 85% of cases in the USA occur amongst African-Americans 
(Monahan et al. 2001). In Africa, HIVAN is the most common presentation in HIV patients with 
CKD (Gerntholtz et al. 2006; Han et al. 2006).  
HIVAN is associated with heavy proteinuria, absence of peripheral oedema, large echogenic 
kidneys and rapid progression to end stage renal disease (D'Agati et al. 1997). Szczech et al (2002) 
showed that 32% of HIV positive patients had proteinuria (> or =1+ on dipstick examination on at 
least 2 consecutive analyses); CD4 counts ≤ 200 cells/µl, detectable HIV RNA level, increasing 
systolic blood pressure, decreasing serum albumin and increasing serum creatinine were all 
associated with the development of renal failure.  
A series of 99 biopsies of HIV positive patients in Chris Hani Baragwanath Hospital, Johannesburg, 
South Africa during 2003 and 2004 categorized the classic HIVAN in 27% and HIVICK (HIV 
immune complex kidney disease) with sub-epithelial immune deposits in 21% (Gerntholtz et al. 
2006).  
Another study at the King Edward Hospital in Durban, South Africa, looked at the prevalence of 
CKD by screening for proteinuria in 615 HIV positive patients. Thirty-eight patients (6%) were 
found to have proteinuria and 32 out of 90 (36%) patients tested had microalbuminuria. Persistent 
microalbuminuria was found in only 7 patients. When biopsied, 6 of these 7 showed the presence of 
HIVAN. In total, 25 out of 30 (83.3%) renal biopsies showed HIVAN (Han et al. 2006).  
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Some work has gone into the various presentations of HIV nephropathy, but there is a paucity of 
information regarding predictors of outcome. A review of 16834 patients from 8 clinics in the 
United Kingdom between 1998 and 2004, identified HIVAN in 61 patients. Of these, 34 (56%) 
developed ESRD. HIVAN prevalence in black patients was 0.93%.There was no additional renal 
benefit in early initiation of HAART, viral suppression or CD4 recovery in the cohort with HIVAN. 
The severity of CKD as quantified on biopsy was the strongest predictor of progression to ESRD. 
There was a statistically significant difference in the group with a higher index of chronic damage 
(ICD) score compared to those with a lower score. The median ICD score for 16 patients that 
developed ESRD was 84, as compared with a score of 31 for 12 patients who maintained stable 
renal function (Post et al. 2008).  
1.5.2  Potential causes of CKD in HIV positive patients 
 
There are a few associations with the various causes of CKD in HIV patients (see Table 10) such as 
hepatitis B and C with Membranous and Membranoproliferative GN. 
 
GLOMERULAR PATTERN 
HIVAN  (HIV associated nephropathy) 
HIVICK (HIV-immune complex kidney disease) 
Immune complex-mediated glomerulonephritis (GN)  
IgA nephritis 
     Postinfectious GN 
     Membranous GN 
     Membranoproliferative GN 
     Mesangial proliferative GN 
     Fibrillary or immunotactoid GN 
  Mixed inflammatory or sclerotic variant 
  Lupus-like nephritis 
Interstitial Nephritis 
Thrombotic microangiopathies 
Minimal change glomerulonephritis 
Diabetic nephropathy 
Hypertensive nephropathy 
 
Table 10   Spectrum of glomerular disease with HIV  (de Silva et al. 2007) 
17 
 
1.6 HIV and electrolyte disorders 
HIV infection is associated with electrolyte and acid base imbalances. These can be attributable to 
HAART, other drugs, infections and other co-morbidities. Table 11 lists the electrolyte and acid-
base abnormalities due to drugs used to treat HIV positive patients. 
Sodium 
Hyponatraemia is frequent in HIV infected individuals, with a reported incidence of 30-60% in 
hospitalized patients (Agarwal et al. 1989). Hyponatraemia is a marker of severe illness and 
prognostic of increased mortality in HIV infected patients (Tang et al. 1993). The common causes 
are volume depletion caused by diarrheoa and vomiting. Important causes also include the 
syndrome of inappropriate anti-diuretic hormone hypersecretion (SIADH) in hospitalized patients 
which is associated with pulmonary and intracranial diseases. This may direct one to identify 
opportunistic infections such as tuberculosis and Pneumocystis jiroveci pneumonia. 
Potassium 
Hypokalaemia is commonly found in patients with diarrhoea and vomiting. Drugs such as 
Amphotericin B and tenofovir can cause hypokalemia by causing renal tubular dysfunction. Drugs 
such as trimethoprim-sulfamethoxazoleand  pentamidine can cause hyperkalaemia. Hyperkalaemia 
and hyponatraemia may be due to mineralocorticoid deficiency. Hyperkalaemia can also be due to 
acute or chronic renal failure.  
Other 
In a prospective cross sectional study of 1232 patients, the clinically relevant electrolyte 
abnormalities in HIV positive patients also included hyperuricaemia (41.3%), hypophosphataemia 
(17.2%) and low bicarbonate (13.6%) (Bagnis et al. 2007). 
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Hypernatraemia 
 
 
Rifampicin, amphotericin B, foscarnet 
 
Hyperkalaemia 
 
 
Ketoconazole, trimethoprim 
 
Hypokalaemia 
 
 
Rifampicin, amphotericin B, didanosine, foscarnet, 
tenofovir 
 
Hypomagnesemia 
 
 
Amphotericin B, pentamidine 
 
Hypocalcemia 
 
 
Didanosine, pentamidine, foscarnet 
 
Hypouricaemia 
 
 
Rifampicin, tenofovir 
 
Hyperuricaemia 
 
 
Didanosine, pyrazanimide, ethambutol 
 
 
Renal tubular 
acidosis 
 
Amphotericin B, trimethoprim, rifampicin, foscarnet, 
cidofovir, Nucleoside- reverse transcriptase inhibitors 
(NRTI),  
Fanconi’s syndrome with tenofovir 
 
 
Normal Anion gap 
metabolic acidosis 
 
 
Diarrheoa 
Adrenal insufficiency 
Renal tubular acidosis  
 
 
 
Raised anion gap 
metabolic acidosis 
 
Type A lactic acidosis : hypotension, hypovolaemia, 
sepsis, diabetic ketoacidosis 
Type B lactic acidosis : drug induced mitochondrial 
toxicity due to zidovudine, didanosine, lamivudine, 
stavudine, zalcitabine 
 
 
Table 11   Electrolyte and acid base disturbances in HIV positive patients (Fabian and Naicker. 2009) 
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1.7 HIV and HAART nephrotoxicity 
AKI is frequently caused by the toxic effects of antiretroviral therapy or nephrotoxic antimicrobial 
substances used in the treatment of opportunistic infections. Drugs associated with nephrotoxicity 
include aminoglycosides, amphotericin B, foscarnet, trimethoprim-sulfamethoxazole, tenofovir, 
indinavir and acyclovir. 
Diabetes mellitus and the metabolic syndrome may be accelerated by lipid abnormalities associated 
with HAART. A study of 5578 patients during 1984-2003 revealed an incidence of hypertension of 
7.3% among HIV positive individuals. The incidence increased significantly after 2 years of 
treatment (Seaberg et al. 2005). The common causes of CKD are diabetes and hypertension and the 
added burden by HAART compounds the numbers of patients with ESRD.  
Nucleotide reverse transcriptase inhibitors 
Tenofovir, adefovir and cidofovir have been associated with renal tubular damage (Verhelst et al. 
2002). Tenofovir has been linked to Fanconi’s syndrome consisting of a defect in the proximal 
tubule, causing loss of glucose, phosphate, calcium, uric acid, amino acids, bicarbonate and tubular 
proteins, which is usually reversible (Izzedine et al. 2005).  
A recent meta-analysis reviewed the renal safety of Tenofovir Disoproxil Fumarate (TDF) in HIV 
infected patients. There were 17 studies (including 9 randomized controlled trials) that met the 
selection criteria and included a median sample size of 517 participants. There was a significantly 
greater loss of kidney function among the TDF recipients compared to the control subjects (mean 
difference in GFR, 3.92ml/min) as well as a greater risk of AKI (risk difference 0.7%). There was 
no evidence of increased risk of severe proteinuria, hypophosphataemia or fractures (Cooper et al. 
2010). 
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Nucleoside Reverse Transcriptase Inhibitors 
Renal toxicity is rare. Case reports with didanosine and lamivudine-stavudine have been associated 
with tubular dysfunction (Izzedine et al. 2005). 
Non-nucleoside Reverse Transcriptase Inhibitors 
Nevirapine, efavirenz and delaviridine have been demonstrated to be safe in controlled trials 
(Roling et al. 2006). 
Protease Inhibitors 
Indinavir has been most frequently associated with adverse renal effects including nephrolithiasis, 
crystalluria, dysuria, papillary necrosis and AKI (Daugas et al. 2005) Antiretroviral therapy given 
in combination with low dose ritonavir increases the toxicity of indinavir (Casado et al. 2000). 
Ritonavir has been associated with reversible renal failure (Bochet et al. 1998). 
Saquinavir and nelfinavir have been demonstrated to be safe in controlled trials, but there has been 
a single case report of them causing renal calculi (Green et al. 1998). 
Atazanavir, amprenavir, fosamprenavir and lopinavir have not been associated with renal toxicity. 
Life expectancy is increasing with the advent of HAART and thus the spectrum of renal disease in 
HIV patients will include an increased prevalence of diabetes mellitus, hypertension and other 
chronic diseases (Roling et al. 2006). 
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1.8  Hypothesis 
 Outcomes of AKI are similar in HIV positive and HIV negative patients. 
  
1.9 Objectives 
1) To describe the presentation of renal failure in HIV positive patients. 
 
2) To determine the clinical and laboratory features of AKI in HIV positive patients. 
 
3) To compare AKI between HIV positive and HIV negative patients with regards to clinical  
features and outcomes. 
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CHAPTER 2    PATIENTS AND METHODS 
2.1 Study Design 
A single-centre retrospective review of patients presenting to the acute renal service of the Division 
of Nephrology at Charlotte Maxeke Johannesburg Academic Hospital, a referral tertiary hospital 
draining the greater Johannesburg area,was conducted during the period 1stOctober2005 until 
31stOctober 2006.Patients were seen daily by the registrar and Nephrology consultant on call for the 
week in the acute renal unit. The study aimed at reviewing data of HIV positive patients with renal 
failure.  Those presenting with AKI were further reviewed to compare data with a randomly chosen 
cohort of HIV negative patients. Young HIV negative patients presenting with renal failure were 
chosen to attempt to age match with the HIV negative group and these were chosen as monthly 
consecutive referrals after the HIV positive patients. 
The inclusion criteria included patients who were 
o over the age of 18 years 
o presented to the CMJAH between 1stOctober 2005 and 31stOctober 2006 
o consulted by the adult renal unit 
The identities of all patients were and will be kept confidential. The first two letters of the name 
and surname of the patients were used as the codename for the patients. After collecting the 
information on the data collection sheet, all data was transformed onto the spreadsheets (see 
Appendix 7 and 8). 
Demographic data, laboratory results and other information was abstracted from the weekly records 
kept in the “acute renal’’ database.  Renal summaries and the hospital files were reviewed where 
available. 
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Ethics approval was granted unconditionally by the University of the Witwatersrand Ethics 
committee. (Clearance certificate M070427)  
Data that was collected included:  
o age  
o sex  
o race 
o ward 
o diagnosis (AKI, AOCRF, CKD) 
o aetiology of renal failure (sepsis, haemodynamic instability, toxins, urological 
obstruction, miscellaneous)  
o co-morbidities 
o hypertension 
o diabetes 
o tuberculosis 
o serum electrolytes (sodium, potassium, chloride, bicarbonate) 
o serum calcium, magnesium, phosphate 
o serum urea & creatinine (admission, inpatient, discharge) 
o days of recovery (from admission to lowest serum creatinine) 
o leucocytes (in blood) 
o haemoglobin 
o platelets 
o albumin 
o CD4    
o hepatitis  
o urine protein-creatinine ratio 
o urine microscopy and culture 
o blood culture 
o dialysis 
o kidney size 
o outcome 
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• Hypertension was defined using the South African Hypertension Society guidelines  
i.e. SBP>140 and/or DBP >90, or known hypertensive patient on medication. 
• Diabetes mellitus was diagnosed by the attending medical doctors. Local SEMDSA 
guidelines were used. 
• Tuberculosis was diagnosed by the identification of acid fast bacilli in sputum, bone 
marrow,TB bactec or by the attending medical doctor’s judgment of the patient’s chestX-
ray. 
• Serum electrolytes including sodium, potassium, chloride and bicarbonate together with 
blood urea and serum creatinine were collected on admission. The lowest serum creatinine 
and the serum creatinine on discharge were collected as well. The days of recovery were 
calculated by reviewing the serial creatinine levels and the lowest levels achieved. 
• Urine dipstix results were obtained where possible.  
• Urine microscopy, culture & sensitivity was obtained.  
Urine leucocyte number and erythrocyte number were obtained. 
• Proteinuria was obtained from a spot urine PCR and/or dipstix proteinuria. 
• The organisms cultured from the blood were documented.  
• Dialysis was initiated according to standard indications (see Table 5). The mode of dialysis 
used was haemodialysis.  
• Kidney size was documented using ultrasonography by the radiology unit. 
• Some patients were treated conservatively, without dialysis. These included foreign 
nationals with CKD (after counseling regarding private funding) and patients deemed to 
have a poor prognosis. 
• Outcome was measured as either recovery or death. 
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Patients were stratified (opinion-based) into 3 groups, namely AKI, AOCRF and CKD. The files 
were reviewed by a senior nephrologist (Dr S Wadee) and myself. The reviewed data that helped 
stratify the groups included:  
o Past medical history of CKD 
o Serum creatinine 
Recovery of serum creatinine within 3 months is defined as AKI.As most 
consultations were in-hospital, data was not available for follow-up. Hence, 
the improvement of renal function was reviewed by the difference in the 
admission creatinine and the lowest creatinine achieved or independence 
from dialysis if previously dialysis requiring. 
o Haemoglobin  
Anaemia cannot be reliably used to diagnose CKD;  moreover in HIV 
patients a low haemoglobin could be attributable to bone marrow failure, 
infiltrations and infections, haemorrhage, haemolysis amongst other causes.  
o Serum calcium and phosphate 
While CKD is associated with a hypocalcaemia and hyperphosphataemia, 
these electrolyte changes are also present in later stages of AKI or with 
specific causes of AKI such as rhabdomyolysis. 
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o Renal sonar 
Small kidneys are associated with CKD. However, there are a few conditions 
that cause enlarged kidneys such as diabetes mellitus, multiple myeloma, 
polycystic kidney disease, renal cell carcinoma, infiltrative conditions such 
as amyloidosis and HIV associated nephropathy. Therefore enlarged kidneys 
could be present in any HIV positive patient with acute or chronic renal 
failure. 
AKI was defined as an improvement in admission serum creatinine >50% (Kellum 2008). This 
group was further subdivided using the RIFLE criteria into ‘Risk’, ‘Injury’ and ‘Failure’. Using a 
serum creatinine of < 97µmol/L as normal (as referenced by the National Health Laboratory 
Service at the CMJAH), the three groups were categorized as below: 
RIFLE classification  serum creatinine (µmol/L) 
Risk serum creatinine > 1,5  < 194 
Injury serum creatinine > 2 195 – 291 
Failure serum creatinine > 3 > 291 
 
Those patients that recovered renal function partially (improvement in serum creatinine less than 
50%) with evidence of underlying CKD were categorized as AOCRF.  
The definition of CKD applies to those patients whose serum creatinine does not improve after 3 
months or with persistent proteinuria. Data that was collected included in-hospital consultations, 
thus strict criteria to the definition could not be observed as follow-up data for up to 3 months was 
not available for most patients, who were lost to follow up. Those patients with small kidneys 
(<9cm) were classified as CKD. 
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2.2 Statistical methods 
Statistical analysis was done using a commercially available package, namely STATISTICA 
(version 9). 
Descriptive statistics was done using measures of location (mean, median ,mode) and measures of 
spread (standard deviation, range) for continuous variables. Frequency distribution tables were used 
for categorical variables. Pie and bar charts were used for categorical variables. 
Bivariate analysis for pairs of categorical variables was done using Pearson’s Chi Square (Fisher’s 
exact when appropriate). The Student’s t-test was used for pairs of normally distributed continuous 
variables. 
The Shapiro Wilk test for normality of data was used for assessment of skewness and kurtosis.   
(see Appendix 5)  
Statistical significance was ascertained at the 5% level (a p-value of less than 0.05 to imply 
significance). 
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CHAPTER 3   RESULTS 
3.1  HIV positive patients presenting with renal failure 
3.1.1  Demographic and clinical data 
In the period reviewed, 684 patients presented with renal failure to the Adult Renal Unit at the 
Charlotte Maxeke Johannesburg Academic Hospital. Of these, 101 patients were HIV positive 
(14.8%). The patients were predominantly black (99 patients) and there were 56 males. The average 
age was 38years ±9.89 (range 21 – 61years). 
Presentation 
Most HIV positive patients presented with AKI (57 patients), followed by CKD (23 patients) and 
lastly AOCRF (21 patients) (Figure 4). 
 
Figure 4    Flow diagram (patient presentation) 
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Aetiology of Renal Failure 
The patients were further classified according to the aetiology of the renal failure (see Table 12). 
o sepsis  
o haemodynamic instability 
o toxin  
o urological obstruction 
o miscellaneous  
Those in the sepsis groups were classified by file review including blood and urine culture and 
sensitivity. Those with haemodynamic instability included pre-renal patients, predominantly those 
dehydrated secondary to gastrointestinal losses but also conditions such as cardiac failure and 
haemorrhage.  
Toxins included contrast agents used for diagnostic scans, ‘Muti’ (traditional medicines), drugs 
such as aminoglycosides and amphotericin B.  
Urological obstruction included those patients presenting with urinary retention secondary to 
masses (infectious or neoplastic), prostatic pathology and drugs.  
Those presentations not included in the above groups were placed into the miscellaneous group. 
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 AKI AOCRF CKD 
N 57 21 23 
Sepsis 34 (60%) 15 (71%) 11 (48%) 
Haemodynamic 11(19%) 2 (10%) 0 
Toxin 5 (9%) 0 3 (13%) 
Obstruction 4 (7%) 0 0 
Miscellaneous 8 (14%) 2 (10%) 5 (22%) 
 
Table 12   Aetiology of renal failure (HIV positive patients) 
 
Location of patients  
The majority of the consultations were from the medical ward (81 patients), followed by the 
Medical Intensive Care Unit , Obstetrics and Gynaecology wards and the smallest numbers coming 
from the surgical wards (Table 13).  
 
 
 
 
Table 13 Ward admissions (HIV positive patients) 
 
 
 
 
 
 
WARD HIV positive  
Medical 81 
ICU 10 
Surgical 4 
Obstetrics & Gynaecology 6 
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Co-morbid conditions 
Chronic diseases 
 
 
 
Table 14   Blood pressure in HIV positive patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Hypertension was present in 11 patients (Table 14) and diabetes mellitus in 6 patients.   
 ALL AKI AOCRF CKD 
     
SBP (mmHg) 123 108 125 157 
DBP (mmHg) 76 69 75 93 
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Infectious Diseases 
Tuberculosis was identified in 22 patients.  
Hepatitis B co-infection was present in 5 patients and Hepatitis C in 2 patients. 
The predominant organism cultured from the blood was S.pneumonia (Table 15). 
Methicillin resistant Staphylococcus aureus (MRSA) was cultured in 4 patients. E.coli and 
K.pneumonia were the most common organisms cultured in the urine.  
 
Renal replacement therapy 
Haemodialysis was initiated in 43 individuals (Table 16). 
 
 
 
 
 ALL  AKI  AOCRF  CKD  
         
Blood Culture  S.pneumonia 5  3  1  1  
                          S. aureus 2  0  0  2  
                          MRSA 4  3  1  0  
                          E.Coli 3  2  1  0  
                          S.typhi 2  2  0  0  
         
Urine                 E.Coli 9  4  3  2  
                          K. pneumonia 4  3  1  0  
 
 
 
 
 
 
 
Table 15   Culture results in HIVpositive patients 
 
 N AKI AOCRF CKD 
     
Dialysed 43 22 8 13 
Table 16   Haemodialysis in HIV positive patients 
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3.1.2 Laboratory data 
Proteinuria 
The average level of protein in the urine was 0.61mg/mmol. As the categories of renal failure progressed 
from acute to chronic, so did the amount of proteinuria, as measured by the urine PCR (see Figure 5). 
 
 
 
                          Figure 5   Urine protein-creatinine ratio  
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CD4 count 
The mean CD4 count was 135cells/µl. More than 50% of the patients had a CD4count below 
100cells/µl. Of interest was that the lowest CD4 counts were found in the AOCRF group (see 
Figure 6). 
 
 
Figure 6    Mean CD4 count (cells/µl) in the 3 categories of renal failure 
 
 
 
Table 17   CD4 count (cells/µl) in HIV positive patients 
 
 
 
CD4 
AKI 
146 AOCRF 
75 
CRF 
170 
  N ALL    
(mean) 
AKI AKI     
(mean) 
AOCRF AOCRF 
(mean) 
CKD CKD 
(mean) 
CD4 88 135.3 49 146.1 18 74.8 20 170.2 
CD4<200 63  36  16  11  
CD4<100 52  33  9  10  
CD4<50 37  21  10  6  
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3.2 HIV positive patients presenting with Acute Kidney Injury 
There were 57 patients who presented with AKI. Amongst this group 7 patients were not included 
in the comparison with HIV negative patients as their data was not sufficient. 
The patients with AKI were divided using the ‘RIFLE’ classification into 3 groups; Risk, Injury and 
Failure (see Table 18).  
RIFLE classification Serum creatinine (mg/dl)  Number of patients with AKI (%) 
Risk serum creatinine > 1,5  4 (8) 
Injury serum creatinine > 2 10 (20) 
Failure serum creatinine > 3 36 (72) 
 
Table 18   RIFLE classification (HIV positive group) 
 
3.3 HIV negative patients presenting with Acute Kidney Injury 
In the HIV negative group, 90 randomly selected patients were evaluated. These HIV negative 
patients were age and gender matched as far as possible from the acute renal unit database. The 
group was also divided using the RIFLE criteria into 3 groups; Risk, Injury and Failure. 
RIFLE classification Serum creatinine (mg/dl)  Number of patients with AKI (%) 
Risk serum creatinine > 1,5  26 (29) 
Injury serum creatinine > 2 24 (27) 
Failure serum creatinine > 3 40 (44) 
 
Table 19   RIFLE classification (HIV negative group) 
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3.4 Comparison between HIV positive and HIV negative patients with AKI 
Acute kidney injury was reviewed by comparing the demographic, clinical and laboratory 
parameters between the HIV positive and HIV negative groups as well as their outcomes. There 
were 50 HIV positive patients and 90 HIV negative patients selected as previously discussed and 
they were further subdivided using the RIFLE classification (Table 20). 
RIFLE classification HIV positive (%) HIV negative (%) 
Risk 4 (8) 26 (29) 
Injury 10 (20) 24 (27) 
Failure 36 (72) 40 (44) 
 
Table 20   Comparison in presentation of AKI 
 
Demographic data included age, sex and race. 
 
Clinical data included aetiology of AKI, wards, dialysis, days to recovery, co-morbid conditions 
such as chronic diseases (hypertension and diabetes mellitus) and infectious diseases (tuberculosis 
and hepatitis) and renal sonar size 
 
Laboratory data included electrolytes, urea and creatinine, haemoglobin, albumin, hepatitis B and 
C, urine and blood cultures. 
 
There were two outcomes assessed; survival and death. 
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3.4.1 Demographic and clinical data 
Age  
HIV positive : The mean age was 37.42 years ± 10.45 (range 21-67 years) 
HIV negative : The mean age was 45.20 years ± 16.97 (range 18-84 years) 
 HIV positive HIV negative 
Survived 37.36 years 49.23 years 
Died 37.46 years 41.49 years 
 
Table 21   Outcome (age) 
Gender 
HIV positive : There were 22 (44%) females and 28 (56%) males. 
HIV negative : There were 35 (39%) females and 55 (61%) males. 
There were more females in the HIV positive group as compared to the HIV negative group  
(44% vs 39%). (p=0.564) 
Males 
 HIV positive (%) HIV negative (%) 
Recovered 28 (56) 48 (53) 
Died 22 (44) 42 (47) 
 
Table 22   Outcome of males 
Females 
 HIV positive (%) HIV negative (%) 
Recovered 22 (44) 42 (47) 
Died 28 (56) 48 (53) 
 
Table 23    Outcome of females 
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Race   
 HIV positive (%) HIV negative (%) 
Black 49 (98) 67 (74) 
White 1 15 
Indian - 6 
Coloured - 2 
 
Table 24    Race (AKI) 
Majority of the HIV positive patients were black (98%) and this was statistically significant when 
compared to the HIV negative group (p<0.0004). 
In the HIV negative group there was a more varied racial grouping. 
Location 
 HIV positive (%) HIV negative (%) 
Medical 37 (74) 43 (48) 
Surgical 4 (8) 22 (24) 
ICU 6 (12) 15 (17) 
Obstetrics/Gynaecology 3 (6) 10 (11) 
 
Table 25    Location of patients referred with AKI 
In the HIV positive group the majority of the patients were from the medical wards (74%) as 
compared to the HIV negative group (48%) (Table 25) and this was statistically significant 
(p<0.0022). The HIV negative patients were more likely to come from the non-medical wards as 
compared to the HIV positive patients.  
 
Table 26    Outcome of AKI according to referring departments 
  HIV positive (%) HIV negative (%) 
Survived Medical 23 (46) 25 (27.8) 
 Surgical 3 (6) 11 (12.2) 
 ICU - 4 (4.4) 
 Obstetrics/Gynaecology 2 (4) 8 (8.8) 
Dead Medical 14 (28) 18 (20) 
 Surgical 1(2) 11 (12.2) 
 ICU 6 (12) 11 (12.2) 
 Obstetrics/Gynaecology 1 (2) 2 (2.2) 
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Aetiology of AKI  
 HIV positive (%) HIV negative (%) 
Sepsis 31 (62) 39 (43) 
Haemodynamic 10 (20)  15 (17) 
Toxin 5 (10)  6 (6) 
Urological obstruction 4 (8)  7 (8) 
Miscellaneous 5(10)  21 (23) 
 
Table 27   Aetiology of AKI 
 
Sepsis was the predominant cause of AKI in both groups but was more common in the HIV 
positive group (Table 27). Figure 7 is a comparison of the different aetiologies of AKI between the 
HIV positive and the HIV negative groups. 
 
 
Figure 7   Comparison of aetiology of AKI in HIV positive and HIV negative patients   
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Renal replacement therapy (Haemodialysis)  
In the HIV positive group 18/50 (36%) patients were dialyzed as compared to the HIV negative 
group where 35/90 (39%) were dialyzed. 
 HIV positive (%) HIV negative (%) 
Survived 7 (14) 20 (22) 
Dead 11 (22) 15 (17) 
 
Table 28    Outcome of patients with AKI that were dialysed 
 
Fluid Therapy 
For those patients that were not dialysed and treated with fluid therapy and antibiotics where 
indicated, 42% of HIV positive patients recovered as compared to 31% of HIV negative patients. 
 HIV positive (%) HIV negative (%) 
Survived 21 (42) 28 (31) 
Dead 11 (22) 27 (30) 
 
Table 29    Outcome of patients with AKI treated with fluid therapy 
 
 
Those patients presenting with AKI that recovered with fluid therapy (i.e. were not dialyzed) were 
evaluated in their days to recovery.  HIV positive patients recovered in 9.79 days ± 6.16 (3-28days) 
and HIV negative patients recovered in 10.06 days ± 5.76 (2-24days). 
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Chronic diseases 
There was only 1 patient with diabetes mellitus and 2 patients with hypertension in the HIV 
positive group, compared to 13 patients with diabetes mellitus and 19 patients with hypertension in 
the HIV negative group. 
 
Infectious Diseases  
In the HIV positive group, 13 patients were diagnosed with tuberculosis as compared to only 2 in 
the HIV negative group. Hepatitis B was present in 2 of the HIV positive patients. 
 
Renal sonar size 
 HIV positive HIV negative 
Right kidney (cm) 12.11 10.96 
Left kidney (cm) 12.21 11.24 
 
Table 30   Renal size on ultrasound 
 
HIV positive patients had larger renal sonar sizes than HIV negative patients (p< 0.0001, t-test).  
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3.4.2 Laboratory and outcome data 
*Characteristics  HIV positive HIV negative p 
 
Number  
  
50 
 
90 
 
     
Electrolytes     
   Na (mmol/l)                                 132 139 <0.0001 
   K   (mmol/l)                                4.9 4.5 0.0426 
   Cl-  (mmol/l)                                98 103 0.0121 
   CO2 (mmol/l)                            14.7 19.4 0.0002 
   Urea (mmol/l)                  (admission) 34.5 23.3 0.0013 
   Creatinine (µmol/l)          (admission) 619 455 0.07 
Calcium (mmol/l)  2.28 2.33 ns 
Magnesium (mmol/l)  1.09 0.93 ns 
Phosphate (mmol/l)                2.49 1.78 0.0004 
Haemoglobin (g/dl)  10.02 10.84 ns 
Albumin (g/dl)  27.17 28.58 ns 
Hepatitis B  2  ns 
Urine PCR   0.26 0.28 ns 
     
Survived (%)               56 52 0.694 
Died (%)                         44 47 0.7173 
     
 
Table 31    Laboratory and outcome data (AKI) 
 
Electrolytes 
HIV positive patients presented more hyponatraemic (p<0.0001, t-test), hyperkalaemic (p=0.0426, 
t-test) and hypochloraemic (p=0.0121, t-test) compared to the HIV negative patients and this was 
statistically significant (see Table 33). HIV positive patients were also more acidotic (p=0.0002, t-
test). Serum calcium and magnesium levels were similar, however HIV positive patients were more 
hyperphosphataemic compared to HIV negative patients, which was statistically significant 
(p=0.0004, t-test). 
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Urea and Creatinine 
HIV positive patients had a higher baseline mean serum creatinine on admission than the HIV 
negative patients. 
 HIV positive HIV negative 
Creatinine (µmol/l)  (admission) 619 ± 407 455 ± 561 
Creatinine (µmol/l)  (lowest) 202 ± 143 170 ± 103 
 
Table 32   Serum creatinine levels 
Excluding those patients that were dialysed, the following observation was made; HIV positive 
patients recovered to a lower serum creatinine than HIV negative patients with supportive care over 
a shorter period. 
 HIV positive HIV negative 
Creatinine (µmol/l)   (lowest) 157 ± 72 184 ± 118 
 
Table 33   Serum creatinine improvement with fluid therapy 
 
Haemoglobin 
Haemoglobin levels were similar and not statistically significant when comparing HIV positive and 
HIV negative patients. 
 HIV positive HIV negative 
Haemoglobin (g/dl) 10.02 ± 3.01 10.84 ± 3.09 
 
Table 34   Haemoglobin levels in AKI patients 
 
Albumin 
Albumin levels were similar and not statistically significant between HIV positive and HIV 
negative patients. 
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 HIV positive HIV negative 
Albumin (g/dl) 27.17 ± 8.37 28.58 ± 8.56 
 
Table 35   Serum albumin levels in patients with AKI 
 
Urine PCR 
 HIV positive HIV negative 
Urine PCR (g/mmol) 0.26 0.28 
 
Table 36   Urine PCR (AKI) 
 
Urine PCR did not differ between the two groups of patients as there was no statistical significance. 
 
 HIV positive HIV negative 
Survived 0.263 0.316 
Dead 0.259 0.234 
 
Table 37   Outcome (urine PCR) 
 
Urine PCR was not a reliable predictor of outcome as this test was only done in 22 of the 90 HIV 
negative patients. 
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CHAPTER 4    DISCUSSION 
4.1 Presentation of renal failure in HIV positive patients 
HIV positive patients presented more commonly with AKI (57 of the 101 patients) than AOCRF 
and CKD. The mean age of the HIV positive patients presenting with renal failure was 38 ± 9.89 
years. Previous studies have shown similar mean ages of HIV positive patients with renal failure 
ranging from 35 years to 46.7 years (Rao et al. 1995; Peraldi et al. 1999; Franceschini et al. 2005; 
Wyatt et al. 2006). Males represented the majority of patients in previous studies (see Appendix 5). 
There were almost equal numbers of males and females reviewed with AKI in this study (56% 
males). 
Patients presenting in our setting with renal failure who were HIV positive were more likely to be 
black. There were 98 out of 101 HIV positive patients with renal failure that were black. The only 
similar study showing 99% of the patients presenting with acute kidney injury to be black was the 
study by Rao et al. The studies by Wyatt, Ibrahim and Franceschini each showed the percentage of 
black patients with acute kidney injury to be 54.5 %, 55% and 61 % respectively. The racial 
predominance is different to other countries which might be due to epidemiological factors and the 
spread of HIV.  In the literature, HIVAN is predominantly found in the black race. The majority race 
in South Africa is black and the predominance of black patients that are HIV positive presenting with 
renal failure is evident.  
The majority of consultations for patients with renal failure that were HIV positive came from the 
medical wards (81%). When the aetiology of renal failure is reviewed, the commonest cause of 
renal failure was sepsis (60%) followed by haemodynamic instability. Urological obstruction was 
the least common cause of renal failure (4%). Sepsis was also the predominant aetiology of renal 
failure in other studies. Rao et al showed that sepsis was the most common aetiology (52%) in 
hospitalized patients. Sepsis was the most frequent cause of AKI in the retrospective review by 
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Peraldi et al, accounting for 75% of cases. Other studies (see Appendix 5) showed that sepsis was 
less common, however these included ambulatory and not hospitalized patients (Franceschini et al. 
2005; Ibrahim et al. 2010). 
AKI patients presented in a hypotensive state more frequently compared to those with AOCRF and 
CKD individuals, with a mean BP of 108/69. This was due to AKI representing 85% of cases of 
haemodynamic instability, including hypovolaemia.  
Hyponatraemia was common amongst all three groups, but most severe in the AKI patients. The 
study by Agarwal et al reported the incidence of hyponatraemia in HIV infected patients as 30-60% 
and Tang et al showed that it was a marker of severe illness and prognostic of increased mortality in 
HIV positive patients. The common causes of hyponatraemia include diarrheoa and vomiting but 
important causes including SIADH must be excluded. 
HIV positive CKD patients presented with more severe hyperkalaemia and acidosis. This could be 
secondary to the renal failure or concomitant drugs such as trimethoprim-sulfamethoxazole. 
Mineralocorticoid deficiency could also account for the hyperkalaemia and also hyponatraemia. 
The mean haemoglobin was 8.44mg/dl which was expectedly lower than the AKI group (9.98 
mg/dl). CKD patients also were appropriately more hypocalcaemic and hyperphosphataemic than 
the other patients in keeping with chronicity.  
The mean CD4 count of all the groups was 135 cells/µl. There were 63% of patients with AKI that 
had CD4 count <200cells/µl. In the study by Franceschini et al only 29% had CD4<200cells/µl. The 
mean CD4 count in the AOCRF patients was almost half (75cells/µl) that of AKI patients    (146 
cells/µl) and CKD (170cells/µl) patients. This could possibly be due to the fact that these patients 
had underlying CKD and with compromised renal function and the lower CD4 count made these 
patients more susceptible to an acute illness warranting admission. 
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S.pneumonia, Methicillin-resistant Staphylococcus aureus, E.coli and Salmonella infections were 
identified more commonly in the AKI group when compared to the CKD group, however in the 
chronic group Staphylococcus aureus was more common.  
Urine leucocytes were present in more than half of all the patients. 
 Urine leucocytes  
AKI 32/57 (65%) 
AOCRF 13/21 (62%) 
CKD 13/23 (57%) 
 
Table 38   Urine leucocytes (HIV positive group) 
 
E.coli was cultured in the urine in all three groups. K. pneumonia was not present in the chronic 
group.  
Urine PCR on admission in the AKI, AOCRF, CKD group was 0.24, 0.58 and 1.25 respectively. 
There was nephrotic range proteinuria in the AOCRF group and significant proteinuria in the CKD 
group (see Figure 8). 
               
   Figure 8    Urine PCR (HIV positive group) 
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4.2 HIV and Acute Kidney Injury 
HIV positive patients with AKI presented with more severe renal failure than HIV negative 
patients. Using the RIFLE classification, 72% of HIV positive patients presented in the most severe 
clinical category (‘Failure’) as compared to 44% of HIV negative patients. Conversely, 29 % of 
HIV negative patients presented in the least severe clinical category (“Risk’) as compared to only 
8% of HIV positive patients.  
The majority of patients in the HIV positive group were black (98%) as compared to the HIV 
negative group (74%) and this was statistically significant (p = 0.0004). There was a more varied 
racial distribution in the HIV negative group. 
HIV positive patients presented more commonly to the medical wards with AKI when compared to 
the HIV negative patients (74% vs 48%).This was statistically significant (p=0.0022). There were 3 
times more HIV negative patients admitted in the surgical wards than HIV positive patients (24% 
vs 8%).  
Sepsis was the predominant cause of AKI in the HIV positive group (62%) and was also the more 
common aetiology when compared to the HIV negative group (43%). HIV positive patients 
presented with toxin ingestion slightly more commonly than HIV negative patients (10% vs 6%) 
and similar presentations with urinary obstruction (8%).  
Chronic diseases such as hypertension and diabetes were more commonly associated with AKI in 
the HIV negative group as compared to the HIV positive group. There were 19 patients diagnosed 
with hypertension and 13 patients with diabetes in the HIV negative group and 2 patients with 
hypertension and 1 patient with diabetes in the HIV positive group.  
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Infectious diseases were more commonly present in the HIV positive group.  Tuberculosis was 
present in 13 of the 50 patients with AKI in the HIV positive group as compared to 2 patients in the 
HIV negative group. Hepatitis B was present in 2 HIV positive patients with AKI.  
Anaemia was more severe in the HIV positive patients with AKI (10.02 vs 10.84g/dl) and HIV 
positive patients presented more hypoalbuminaemic than HIV negative patients (27.17 vs 
28.58g/dl).  
In keeping with the literature (Agarwal et al. 1989), the HIV positive patients presented more 
hyponatraemic than the HIV negative patients. The HIV positive patients also presented more 
hyperkalaemic, hypochloraemic and more acidotic than HIV negative patients with AKI. HIV 
positive patients with AKI also presented with higher magnesium and phosphate levels than the 
HIV negative patients.  
HIV positive patients with AKI had larger renal sizes using ultrasonography than HIV negative 
patients (Right 12.11cm vs 10.96cm ; Left 12.21 vs 11.24cm).  
 
4.3 Outcome of renal failure in HIV positive patients 
The two outcomes observed were survival and death. Overall 33 of the 101 HIV positive patients 
died, 22 in the AKI group, 6 in the AOCRF group and 5 in the CKD group.  
Focusing on the AKI group the following observations were made.  
There were more females in the HIV positive group as compared to the HIV negative group (44% 
vs 39%), but gender did not have an impact on outcome.  
All 6 HIV positive patients with AKI admitted to ICU died. 
50 
 
 
An equal percentage of HIV positive patients that were dialyzed and those that were treated with 
fluid therapy died (22%). More HIV positive patients recovered with fluid therapy compared to 
HIV negative patients (42% vs 31%), suggesting that volume depletion was frequent in this group. 
Those HIV positive that did recover with fluid therapy, did so sooner than HIV negative patients 
(9.79 days vs 10.06 days). 
Urine PCR was measured in 27/50 HIV positive patients with AKI and there was not much 
difference in the values when recovery and death were compared. The HIV negative patients that 
recovered had more proteinuria than those that died (0.316 vs 0.234). 
 
 
 
HIV positive (n = 27) HIV negative (n  = 22) 
Survived 0.263 0.316 
Dead 0.259 0.234 
 
Table 39   Outcome (urine PCR) 
 
Using urine PCR as an indicator for triaging patients according to chronicity of kidney failure had 
its limitations as this investigation was only done in 22 of the 90 HIV negative patients reviewed. 
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 HIV positive (%) HIV negative (%) p 
Survived              56 52 0.694 
Died                   44 47 0.7173 
 
Table 40 Outcome (AKI) 
 
When reviewing the International literature (see Appendix 5), it is evident that AKI in HIV positive 
patients carries a high mortality; however there was no statistically significant difference in 
outcome between the two groups, hence it can be stated that the outcomes of HIV positive and HIV 
negative patients presenting with AKI were similar. 
 
 
 
4.4 Conclusion   
Outcomes of AKI are similar in HIV positive and HIV negative patients with adequate supportive 
care.  
HIV positive patients should be treated acutely just as HIV negative patients. Dialysis should be 
offered when indicated and aggressive fluid resuscitation, antibiotics as well as other supportive 
care should be emphasized as it is likely that a higher percentage of patients will recover.   
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4.5  Limitations 
This was a retrospective review, thus the completeness of data collection was not fully satisfactory. 
A prospective study would have created more validity.  
Acute kidney injury has many different definitions. The ‘RIFLE’ classification is universally used, 
however different laboratories use different serum creatinine levels and many centers do not 
accurately measure urine output. We were limited as the baseline serum creatinine used was the 
admission creatinine and most of the patients were managed as inpatients and did not return to 
follow up as outpatients after discharge. Thus the definition of AKI as having normal renal function 
at 90 days could not be fulfilled. Thus the term ‘probable AKI’ would be more appropriate. 
Some investigations (e.g. urine PCR) were not equally conducted in all patients in the HIV positive 
and HIV negative groups.  
The patients in the two groups were not ideally matched, hence direct comparison would have been 
better in a prospective study. 
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Appendix 1 
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Appendix 2 
DATA COLLECTION SHEET 
 
Date of admission: ___________________   HIV Yes  No  
Name :   ___________________ 
Hospital No. :  ___________________ 
Age:   ____ 
Sex:   M   F  
 
Race:   B  W  C  I   
 
Renal Failure: AKI    ____ 
  ACUTE ON CHRONIC ____ 
  CKD    ____ 
 
Co-Morbidities:  
_____________________________________________________________________  
 
Dialysed:   Yes  No  
 
  (admission) (lowest) (discharge) 
Urea  ____  ____  _____ 
Creatinine ____  ____  _____ 
 
Admission results 
Hb     ____     
WCC    ____ 
Platelets   ____ 
Na    ____ 
K    ____ 
Cl    ____ 
CO2    ____ 
Ca    ____ 
Mg    ____ 
PO4    ____ 
U.A    ____ 
Urine PCR   ____ 
Albumin   ____ 
CD4    ____ 
Hepatitis studies  ____ 
Renal size (sonar)  ____ ____ 
Other    ________________    
 
Not qualifying for dialysis programme  ______ 
 
Outcome: Renal Recovery/Discharge  ______ 
  RIP     ______ 
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                          Summary of HIV positive patients                          Appendix 3  
 
  N ALL    
(mean) 
AKI AKI     
(mean) 
AOCRF AOCRF 
(mean) 
CKD CKD 
(mean) 
         
N 101  57  21  23  
         
Aetiology  Sepsis 60  34  15  11  
                 Haemodynamic 13  11  2  0  
                 Toxin 8  5  0  3  
                 Urological obstruction 4  4  0  0  
                 Miscellaneous 15  8  2  5  
         
DIALYSED 43  22  8  13  
         
SBP (mmHg) 77 123 42 108 18 125 17 157 
DBP (mmHg) 77 76 42 69 18 75 17 93 
         
Na    (mmol/l) 101 133 57 132.42 21 134.43 23 133.09 
K      (mmol/l) 101 4.96 57 4.92 21 4.83 23 5.18 
Cl     (mmol/l) 101 99.12 57 98.23 21 102.10 23 98.61 
CO2  (mmol/l) 101 14.02 57 14.97 21 14.29 23 11.44 
Urea (mmol/l)                      (admission)  101 38.60 57 35.42 21 32.76 23 51.83 
Serum creatinine (µmol/l)   (admission) 101 827.50 57 633.57 21 677.95 23 1444.74 
Urea (mmol/l)                      (lowest) 77 18.40 47 12.94 15 27.30 15 23.44 
Serum creatinine  (µmol/l)  (lowest) 77 370.23 47 209.96 15 419.27 15 823.4 
Duration of renal recovery (days) 76 14.96 47 17.17 15 10.93 14 11.86 
Urea (mmol/l)                        (discharge) 92 56.87 50 61.52 21 52.76 21 49.91 
Serum creatinine (µmol/l)    (discharge) 57 653.61 26 418.31 15 619.20 16 1068.25 
White cell count 101 11.12 57 10.72 21 10.76 23 12.44 
Haemoglobin (g/dl) 101 9.35 57 9.98 21 8.66 23 8.44 
Platelets (x109/l) 100 269.09 57 262.77 20 288.90 23 267.52 
Albumin (g/dl) 95 26.76 53 26.60 19 27.26 23 26.70 
Hepatitis B 5  2  0  3  
Hepatitis C 2  1  1  0  
CD4 count   (cells/µl) 88 135.31 49 146.08 18 74.78 20 170.15 
CD4 <200 63  36  16  11  
CD4 <100 52  33  9  10  
CD4 <50 37  21  10  6  
Ca (mmol/l) 92 2.27 50 2.28 19 2.29 23 2.25 
Mg (mmol/l) 91 1.04 49 1.11 19 0.94 23 1.00 
PO4(mmol/l) 91 2.46 49 2.49 19 1.99 23 2.80 
Uric acid (mg/dl) 10 0.60 4 0.70 3 0.57 3 0.49 
Blood Culture  S.pneumonia 5  3  1  1  
                        Staphylococcus 2  0  0  2  
                        MRSA 4  3  1  0  
                        E.Coli 3  2  1  0  
                        Salmonella 2  2  0  0  
Urine               leucocytes+ 58  32  13  13  
                       erythrocytes + 40  20  10  10  
Urine PCR 67 0.61 31 0.24 18 0.58 18 1.25 
Urine               E.Coli 9  4  3  2  
                        K.pneumonia 4  3  1  0  
         
Conservative 25  7  5  13  
Survived 43  28  10  5  
Died 33  22  6  5  
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Comparison of Acute kidney injury                  Appendix 4 
    
 
*Characteristics 
 HIV positive HIV negative p 
Number   50 90  
 
Age (years)    mean 37.42 45.20 ns 
Sex  male 
female 
28 (56) 
22 (44) 
55 (61) 
35 (39) 
ns 
    ns 
 
Race                
 
 
Black         
White 
Coloured 
Indian        
 
49 (98) 
1 
- 
- 
 
67 (74) 
15 (17) 
2 
6 
 
 
0.0004 
 
Wards         
 
 
Medical     
Surgical 
ICU 
Gynae 
 
37 (74) 
4 (8) 
6 (12) 
3 (6) 
 
43 (48) 
22 (24) 
15 (17) 
10 (11) 
 
 
0.0022 
 
Aetiology     
 
 
sepsis               
haemodynamic 
toxin 
urological obstruction                
miscellaneous 
 
31 (62) 
10 (20) 
5  (10) 
4 (8) 
5  (10) 
 
39 (43) 
15(17) 
6 (7) 
7 (8) 
21 (23) 
 
 
Hypertension   2 (4) 19 (21) ns 
Diabetes     2 (4) 13 (14) ns 
Tuberculosis            13 (26) 2 (2) <0.0001 
Dialysis  18 (36) 35 (39) ns 
    ns 
Renal size (cm)   
 
Right kidney  
Left kidney 
12.11 
12.21 
10.96 
11.24 
<0.0001 
<0.0001 
     
Electrolytes     
   Na               (mmol/l)  132 139 <0.0001 
   K                 (mmol/l)  4.9 4.5 0.0426 
   Cl-(mmol/l)  98 103 0.0121 
   CO2(mmol/l)  14.7 19.4 0.0002 
   Urea            (mmol/l) admission 34.5 23.3 0.0013 
   Creatinine   (µmol/l) admission 619 455 0.07 
Calcium         (mmol/l)  2.28 2.33 ns 
Magnesium    (mmol/l)  1.09 0.93 ns 
Phosphate      (mmol/l)  2.49 1.78 0.0004 
Haemoglobin (g/dl)  10.02 10.84 ns 
Albumin         (g/dl)  27.17 28.58 ns 
Hepatitis B  2   
Urine PCR   0.26 0.28 ns 
     
Survived (%)               56 52 0.694 
Died (%)                         44 47 0.7173 
     
